APRIL MOTOVIDLAK: Open Payments
NPI 1336397942 · CENTREVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,559 in 41 payments from 20 companies in 2025. Trend: 2023 $1,892 · 2024 $2,217 · 2025 $1,559
Food & beverage: $1,309Long term medical supply or device loan: $250
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 8 | $369 |
| AstraZeneca Pharmaceuticals LP | 5 | $160 |
| E.R. Squibb & Sons, L.L.C. | 2 | $150 |
| Genmab U.S., Inc. | 2 | $145 |
| Gilead Sciences, Inc. | 2 | $118 |
| SOBI, INC | 2 | $94 |
| Janssen Biotech, Inc. | 2 | $79 |
| GENZYME CORPORATION | 3 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $59 |
| PFIZER INC. | 2 | $47 |
Products named: KISQALI, OPDIVO, Epkinly, Trodelvy, RYBREVANT, Vonjo, FRUZAQLA, PADCEV.
Industry payments across MD — which companies pay providers there.
